Ameriprise Financial Inc. raised its holdings in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) by 8.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 307,087 shares of the specialty pharmaceutical company’s stock after acquiring an additional 24,685 shares during the period. Ameriprise Financial Inc. owned 0.59% of SciClone Pharmaceuticals worth $3,439,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also modified their holdings of the business. Profund Advisors LLC purchased a new stake in SciClone Pharmaceuticals during the 2nd quarter worth $113,000. Piedmont Investment Advisors LLC purchased a new position in SciClone Pharmaceuticals in the 2nd quarter valued at about $123,000. Susquehanna International Group LLP purchased a new position in SciClone Pharmaceuticals in the 2nd quarter valued at about $142,000. BNP Paribas Arbitrage SA boosted its position in SciClone Pharmaceuticals by 54.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 16,140 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 5,658 shares during the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in shares of SciClone Pharmaceuticals in the 2nd quarter valued at about $195,000. Institutional investors own 72.80% of the company’s stock.
Shares of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) opened at $11.15 on Thursday. The stock has a market cap of $581.94 and a PE ratio of 12.97. SciClone Pharmaceuticals, Inc. has a 12 month low of $8.55 and a 12 month high of $11.43.
TRADEMARK VIOLATION NOTICE: “SciClone Pharmaceuticals, Inc. (SCLN) Shares Bought by Ameriprise Financial Inc.” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/18/ameriprise-financial-inc-has-3-44-million-holdings-in-sciclone-pharmaceuticals-inc-scln.html.
SciClone Pharmaceuticals Company Profile
SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.
Receive News & Ratings for SciClone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SciClone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.